The FDA’s recent approval of transcranial magnetic stimulation (TMS) for adolescents with Major Depressive Disorder (MDD) marks a watershed moment in mental health care. TMS is a non-invasive therapy that uses magnetic pulses to stimulate underactive regions of the brain, restoring healthy rhythm without medication, anesthesia, or downtime. Already a lifeline for adults, the treatment is now cleared and covered for teens—turning what was once an out-of-pocket luxury into an insurance-backed option.

For Phoenix families, the timing could not be more urgent. According to the CDC, nearly 1 in 5 U.S. adolescents reports a major depressive episode each year, and suicide remains the second leading cause of death among teens. Clinical research underscores the need for alternatives: a Mayo Clinic study found that response rates to antidepressants in adolescents hover at just 40–60%, with side effects often leading to early discontinuation. By contrast, peer-reviewed studies of TMS in youth show remission rates as high as 52% in treatment-resistant depression (Croarkin et al., 2021).

“Insurance companies have too often been the gatekeepers of suffering, forcing families to fight or beg for care. This FDA approval tears down that barrier, making a safe and effective treatment more accessible to adolescents struggling with depression,” said Dr. Houshang Aminian, MD, Medical Director at American TMS Clinics. “TMS has proven especially valuable for those who do not respond to psychotherapy or antidepressant medications, or who cannot tolerate their side effects. In fact, most patients experience negligible side effects from TMS.”

Why This Matters for Teens
Adolescence is a pivotal stage for brain development. Depression during these years doesn’t just cause temporary distress—it can derail education, friendships, and long-term growth. Traditional antidepressants have long been the first line of defense, but outcomes remain mixed. Some medications can even heighten suicidal thinking in young people (March et al., 2004).

“TMS doesn’t just manage symptoms,” said Juliane Popelko, CEO of American TMS Clinics. “It restores balance to the brain itself. We see kids re-engage with their families, laugh again, and plan for their futures. That’s not just improvement; it’s transformation.”

What Families in Phoenix Need to Know

• FDA Green Light for Teens — TMS is now FDA-approved for adolescents with Major Depressive Disorder using The Apollo by Neurocare.
• Insurance Finally Steps Up — Major commercial insurers are beginning to cover adolescent TMS, often reducing out-of-pocket costs to nothing more than a co-pay (sometimes $0).
• 1 in 5 Teens Struggle — According to the CDC, nearly 20% of U.S. adolescents report a major depressive episode each year; suicide is now the second leading cause of death among teens.
• Proven Results — Clinical research shows remission rates up to 52% in treatment-resistant adolescent depression with TMS (Croarkin et al., 2021), far exceeding the modest success of medications.
• Help for the Whole Family — American TMS Clinics also provides TMS for adults with depression, OCD, and anxious depression, creating continuity of care for parents and teens alike.

Inside the Clinic, Proof of Healing
At American TMS Clinics, treatment begins with a 20-channel EEG that delivers a visual “snapshot” of brain activity. Over the course of therapy, families can see healthier wave patterns emerge, a clear sign of progress. “Some patients are able to taper off medications entirely,” said Dr. Aminian. “For others, it’s the first time they’ve experienced real relief.”

For adolescents who often feel reduced to a chart number or prescription, the difference is striking. “Our work is measured in life-changing milestones: a smile, a return to school, a breakthrough at home. That’s what drives us every day,” added CEO Juliane Popelka.

From Denials to Access
Until this year, most insurers routinely denied coverage for adolescent TMS, forcing parents into impossible financial choices. With FDA clearance, that barrier has finally been removed. “This is a long-fought-for achievement,” said Dr. Houshang Aminian, MD, Medical Director at American TMS Clinics. “Insurers can no longer hide behind red tape. These kids deserve care, and we are ready to deliver it.”

FDA approval for adolescent TMS represents more than a new billing code—it marks the dawn of a new standard of care. With dual board certification in child and adolescent and adult psychiatry, Dr. Aminian and American TMS Clinics are uniquely positioned to lead this next chapter. “This is just the beginning,” Dr. Aminian added. “We’re building a future where no teen who needs help is shut out—where recovery is accessible, affordable, and lasting.”

For more information, visit American TMS Clinics.